STOCK TITAN

FOXO Technologies (FOXO) majority owner approves reverse split and files 14C

(Moderate)
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

FOXO Technologies Inc. reports that on August 13, 2026, Rennova Health, Inc., which is controlled by FOXO’s CEO and acts as the majority stockholder, approved corporate actions by written consent, including a planned reverse stock split. As of that record date, this majority stockholder held approximately 99.12% of FOXO’s voting rights directly or through proxy, and the Board of Directors approved the action by unanimous written consent the same day.

FOXO filed a preliminary Information Statement on Schedule 14C on August 14, 2026. A definitive Schedule 14C will be mailed to stockholders of record as of the August 13, 2026 record date, and the reverse split will become effective no earlier than 20 days after mailing, subject also to notice and processing under FINRA Rule 6490. Further details on the reverse split are described in the Schedule 14C.

Positive

  • None.

Negative

  • None.
Item 5.07 Submission of Matters to a Vote of Security Holders Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Majority voting control 99.12% of voting rights Held by Rennova Health, Inc. as of the August 13, 2026 record date
Reverse split effective period No earlier than 20 days After mailing the definitive Schedule 14C to stockholders of record
Record Date August 13, 2026 Determines stockholders entitled to notice of the action approved by written consent
PRE 14C filing date August 14, 2026 Preliminary Information Statement on Schedule 14C filed regarding the reverse split
Record Date financial
"is the record date (the “Record Date”) for the determination of stockholders"
The record date is the specific day when a company determines which shareholders are eligible to receive a dividend or participate in an upcoming vote. It’s like a cutoff date; if you own the stock on that day, you get the benefits or voting rights. This date matters because it decides who qualifies for certain company benefits.
Schedule 14C regulatory
"filed a preliminary Information Statement on Schedule 14C"
Schedule 14C is an SEC filing that companies use to send an official information statement to shareholders when they are not asking for proxy votes. It lays out key facts about corporate actions—such as reorganizations, related-party transactions, or changes in governance—so investors can understand what’s happening without being asked to vote, like receiving a detailed neighborhood notice about a rule change rather than a petition. Because it provides formal, regulated disclosure, Schedule 14C helps investors verify claims, weigh potential impacts on ownership or value, and hold management accountable.
Reverse Split financial
"The Reverse Split will then be effective no earlier than 20 days after the mailing"
A reverse split is when a company reduces the number of its outstanding shares by combining several existing shares into one new share, so the price per share rises proportionally while the company’s overall value stays the same. Investors care because it can make a stock appear more respectable or meet exchange rules — like turning many small coins into a single larger bill — but it can also signal financial trouble and often affects trading liquidity and investor perception.
FINRA Rule 6490 regulatory
"required to provide notice to, and have its submission processed by, the Financial Industry Regulatory Authority (“FINRA”) pursuant to FINRA Rule 6490"

FAQ

What corporate action did FOXO (FOXO) announce in this report?

FOXO Technologies Inc. disclosed that its majority stockholder approved a reverse stock split by written consent on August 13, 2026. Details of the reverse split are described in a Schedule 14C information statement filed on August 14, 2026.

Who is the majority stockholder of FOXO (FOXO) and how much voting control do they have?

The majority stockholder is Rennova Health, Inc., which is controlled by FOXO’s CEO. As of August 13, 2026, it held approximately 99.12% of the company’s voting rights, directly or through proxy.

When will the FOXO (FOXO) reverse split become effective?

The reverse split will become effective no earlier than 20 days after mailing the definitive Schedule 14C to stockholders of record. Effectiveness also depends on providing notice to and having the action processed by FINRA under Rule 6490.

What SEC filing did FOXO (FOXO) submit regarding the approved reverse split?

FOXO submitted a preliminary Information Statement on Schedule 14C on August 14, 2026. A definitive Schedule 14C will be mailed to stockholders of record as of August 13, 2026 to describe the reverse split and the approved actions.

Did FOXO’s (FOXO) Board of Directors support the reverse split?

Yes. The Board of Directors approved the action, including the reverse split, by unanimous written consent on August 13, 2026, the same date the majority stockholder executed its written consent approval.

What regulatory steps are required for the FOXO (FOXO) reverse split besides stockholder notice?

In addition to mailing the definitive Schedule 14C, the company must provide notice to the Financial Industry Regulatory Authority (FINRA) and have its submission processed in accordance with FINRA Rule 6490 before the reverse split becomes effective.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
false 0001812360 0001812360 2026-08-13 2026-08-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date Earliest Event Reported): August 13, 2026

 

FOXO TECHNOLOGIES INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-39783   85-1050265

(State or Other Jurisdiction

of Incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

477 South Rosemary Avenue

Suite 224

West Palm Beach, FL

  33401
(Address of Principal Executive Offices)   (Zip Code)

 

(612) 800-0059

(Registrant’s telephone number, including area code)

 

 

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
N/A        

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 

 

 

 

Item 5.07Submission of Matters to a Vote of Security Holders.

 

On August 13, 2026, Rennova Health, Inc. (which is controlled by the Company’s CEO) (the “Majority Stockholder”), a shareholder representing a majority of the voting control of the Company, approved certain actions by written consent (the “Written Consent”). August 13, 2026, the date the Written Consent was delivered to the Company, is the record date (the “Record Date”) for the determination of stockholders entitled to notice of the action approved by the Written Consent. As of the Record Date, the Majority Stockholder held approximately 99.12% of the Company’s voting rights directly or through proxy. The Board of Directors approved the below action by unanimous written consent on August 13, 2026. Pursuant to the Written Consent, the Majority Stockholder approved:

 

1.An amendment (the “Amendment”) to the Company’s Certificate of Incorporation, as amended (the “Certificate of Incorporation”), to effect a reverse stock split of the Company’s issued and outstanding Class A Common Stock (the “Common Stock”) at any time before June 30, 2027, at a ratio ranging from one-for-fifty (1:50) to one-for-one thousand (1:1,000) (the “Reverse Split”), with each fractional share rounded up to the nearest whole share and with the exact ratio within such range to be determined at the sole discretion of the Company’s Board of Directors (the “Board”), without further approval or authorization of the Company’s stockholders before the filing of an amendment to the Certificate of Incorporation effecting the proposed Reverse Split. The Board authorized the Reverse Split solely in connection with, and for the purpose of facilitating, an application to list the Common Stock on a senior national securities exchange, specifically The Nasdaq Stock Market LLC or NYSE American LLC (the “Uplisting”), and will not effect the Reverse Split for any other purpose. For additional information regarding the Reverse Split, stockholders are encouraged to review the Company’s recent filings with the SEC, including the Company’s most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q.

 

The Company has filed a preliminary Information Statement on Schedule 14C with the U.S. Securities and Exchange Commission with respect to the matter approved by the Majority Stockholder (the “PRE 14C”) on August 14, 2026 and, as soon as it may do so, will mail the definitive Information Statement on Schedule 14C to its stockholders of record as of the Record Date. The Reverse Split will then be effective no earlier than 20 days after the mailing. In connection with the Reverse Split, the Company is also required to provide notice to, and have its submission processed by, the Financial Industry Regulatory Authority (“FINRA”) pursuant to FINRA Rule 6490. Further detail regarding the Reverse Split is found in the PRE 14C.

 

2

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  FOXO Technologies Inc.
     
Date: August 14, 2026 By: /s/ Seamus Lagan
  Name: Seamus Lagan
  Title: Chief Executive Officer

 

3

Filing Exhibits & Attachments

3 documents